Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Treasury Shares (2018 - 2026)

Bicycle Therapeutics (BCYC) has disclosed Treasury Shares for 6 consecutive years, with $2.8 million as the latest value for Q1 2026.

  • For Q1 2026, Treasury Shares rose 45.12% year-over-year to $2.8 million; the TTM value through Mar 2026 reached $2.8 million, up 45.12%, while the annual FY2025 figure was $1.5 million, 129.46% up from the prior year.
  • Treasury Shares hit $2.8 million in Q1 2026 for Bicycle Therapeutics, up from $1.5 million in the prior quarter.
  • Across five years, Treasury Shares topped out at $2.8 million in Q1 2026 and bottomed at $187725.0 in Q1 2022.
  • Average Treasury Shares over 5 years is $891627.2, with a median of $674262.0 recorded in 2024.
  • Year-over-year, Treasury Shares skyrocketed 141.08% in 2023 and then surged 45.12% in 2026.
  • Bicycle Therapeutics' Treasury Shares stood at $187725.0 in 2022, then soared by 74.11% to $326848.0 in 2023, then skyrocketed by 106.29% to $674262.0 in 2024, then surged by 129.46% to $1.5 million in 2025, then soared by 79.81% to $2.8 million in 2026.
  • According to Business Quant data, Treasury Shares over the past three periods came in at $2.8 million, $1.5 million, and $1.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.